Axiom Investors LLC DE Sells 15,521 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Axiom Investors LLC DE reduced its stake in Supernus Pharmaceuticals, Inc. by 22.2%, selling 15,521 shares and owning approximately 0.10% of the company valued at $1,781,000.
• Insider trading was notable, with CEO Jack A. Khattar selling 140,000 shares for over $5.88 million, resulting in an 11.96% decrease in his ownership.
• Analyst ratings for Supernus Pharmaceuticals have improved, with Zacks Research upgrading it from a "strong sell" to a "hold," and other analysts giving it a consensus rating of "Moderate Buy".

Axiom Investors LLC DE lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,375 shares of the specialty pharmaceutical company's stock after selling 15,521 shares during the quarter. Axiom Investors LLC DE owned approximately 0.10% of Supernus Pharmaceuticals worth $1,781,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Raiffeisen Bank International AG bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals in the first quarter worth $30,000. Versant Capital Management Inc raised its holdings in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals in the first quarter worth $41,000. Finally, GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter worth $42,000.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $45.82 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $46.79. The business has a fifty day moving average price of $38.29 and a 200-day moving average price of $34.24. The company has a market capitalization of $2.57 billion, a PE ratio of 39.84 and a beta of 0.79.

Insider Activity

In other news, CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at $43,288,289.66. This trade represents a 11.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 235,184 shares of company stock valued at $10,174,149. 8.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday, August 29th. Finally, Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.